JP2018033454A5 - - Google Patents

Download PDF

Info

Publication number
JP2018033454A5
JP2018033454A5 JP2017161826A JP2017161826A JP2018033454A5 JP 2018033454 A5 JP2018033454 A5 JP 2018033454A5 JP 2017161826 A JP2017161826 A JP 2017161826A JP 2017161826 A JP2017161826 A JP 2017161826A JP 2018033454 A5 JP2018033454 A5 JP 2018033454A5
Authority
JP
Japan
Prior art keywords
seq
humanized anti
amino acid
acid sequence
htfr antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017161826A
Other languages
English (en)
Japanese (ja)
Other versions
JP6993814B2 (ja
JP2018033454A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018033454A publication Critical patent/JP2018033454A/ja
Publication of JP2018033454A5 publication Critical patent/JP2018033454A5/ja
Priority to JP2021200504A priority Critical patent/JP7232889B2/ja
Application granted granted Critical
Publication of JP6993814B2 publication Critical patent/JP6993814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017161826A 2016-08-25 2017-08-25 抗体融合蛋白質の製造方法 Active JP6993814B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021200504A JP7232889B2 (ja) 2016-08-25 2021-12-10 抗体融合蛋白質の製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016164901 2016-08-25
JP2016164901 2016-08-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021200504A Division JP7232889B2 (ja) 2016-08-25 2021-12-10 抗体融合蛋白質の製造方法

Publications (3)

Publication Number Publication Date
JP2018033454A JP2018033454A (ja) 2018-03-08
JP2018033454A5 true JP2018033454A5 (enExample) 2020-06-25
JP6993814B2 JP6993814B2 (ja) 2022-01-14

Family

ID=61246169

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017161826A Active JP6993814B2 (ja) 2016-08-25 2017-08-25 抗体融合蛋白質の製造方法
JP2021200504A Active JP7232889B2 (ja) 2016-08-25 2021-12-10 抗体融合蛋白質の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021200504A Active JP7232889B2 (ja) 2016-08-25 2021-12-10 抗体融合蛋白質の製造方法

Country Status (11)

Country Link
US (1) US11512135B2 (enExample)
EP (1) EP3505538B1 (enExample)
JP (2) JP6993814B2 (enExample)
KR (1) KR102318480B1 (enExample)
CN (1) CN109641971B (enExample)
AU (1) AU2017316955B2 (enExample)
BR (1) BR112019003622A2 (enExample)
CA (1) CA3034589A1 (enExample)
MX (1) MX389073B (enExample)
SG (1) SG11201901495YA (enExample)
WO (1) WO2018038243A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250073514A (ko) 2015-06-24 2025-05-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
US11130815B2 (en) 2015-06-24 2021-09-28 Jcr Pharmaceuticals Co., Ltd. Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
TWI761413B (zh) 2016-12-26 2022-04-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
WO2018124107A1 (ja) 2016-12-26 2018-07-05 Jcrファーマ株式会社 Bdnfを含む融合蛋白質
JP7188944B2 (ja) * 2017-09-07 2022-12-13 Jcrファーマ株式会社 水性医薬組成物
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
MX2020008041A (es) * 2018-02-05 2020-09-25 Japan Chem Res Metodo para suministrar farmaco al musculo.
EP3560945A1 (en) * 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
JP6951051B2 (ja) * 2018-05-24 2021-10-20 HOYA Technosurgical株式会社 吸着剤の生産方法
KR102692543B1 (ko) * 2018-10-26 2024-08-07 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
CN114656565B (zh) * 2020-12-23 2024-04-23 广东菲鹏制药股份有限公司 一种抗pd-l1抗体及其应用
JP2024507118A (ja) * 2021-02-11 2024-02-16 デナリ セラピューティクス インコーポレイテッド 抗トランスフェリン受容体融合タンパク質及びその使用方法
MX2023010523A (es) 2021-03-09 2023-09-20 Japan Chem Res Metodo para producir una proteina de fusion de anticuerpo-enzima lisosomica.
US20250059292A1 (en) * 2021-12-28 2025-02-20 Jcr Pharmaceuticals Co., Ltd. Fusion Protein of Anti-Transferrin Receptor Antibody and Physiologically Active Protein for Safe Gene Therapy
JPWO2024010067A1 (enExample) * 2022-07-08 2024-01-11
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537273A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
JP2008523842A (ja) * 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗il−12抗体、エピトープ、組成物、方法および用途
JP5065391B2 (ja) 2006-12-06 2012-10-31 日本ケミカルリサーチ株式会社 ヒトエリスロポエチンの製造方法
MX2009006398A (es) * 2006-12-12 2009-06-23 Biorexis Pharmaceutical Corp Genotecas de proteinas de fusion de transferrina.
JP2009273427A (ja) 2008-05-16 2009-11-26 Jcr Pharmaceuticals Co Ltd 組換え体ヒトfshの製造方法
US8058407B2 (en) 2008-10-31 2011-11-15 Wyeth Llc Purification of acidic proteins using ceramic hydroxyapatite chromatography
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
JP6018572B2 (ja) 2011-01-25 2016-11-02 Jcrファーマ株式会社 組換えヒトイズロン酸−2−スルファターゼの製造方法
AU2012344700A1 (en) * 2011-12-01 2014-06-19 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
US9994641B2 (en) 2013-12-25 2018-06-12 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody that passes through blood-brain barrier
JP6071018B2 (ja) 2014-10-31 2017-02-01 Jcrファーマ株式会社 組換えヒトDNaseIの製造方法
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins

Similar Documents

Publication Publication Date Title
JP2018033454A5 (enExample)
JP2017176174A5 (enExample)
EA201200277A1 (ru) Антитела против респираторного синцитиального вируса (pcb) и способы их применения
JP2010515717A5 (enExample)
JP2019524645A5 (enExample)
JP2012507294A5 (enExample)
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
FI4074331T3 (fi) Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
JP2012025737A5 (enExample)
JP2012025766A5 (enExample)
JP2005120106A5 (enExample)
JP2018530331A5 (enExample)
JP2012511913A5 (enExample)
JP2013172734A5 (enExample)
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
JP2010521147A5 (enExample)
JP2015212284A5 (enExample)
JP2015527366A5 (enExample)
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
RU2021134101A (ru) Модифицированная j-цепь
JP2018504907A5 (enExample)
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
JP2018537415A5 (enExample)
RU2018108836A (ru) ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ